Adaptive Biotechnologies Corp (ADPT) stock is surging 11.41% in pre-market trading on Friday, following the company's impressive first-quarter 2025 earnings report that exceeded analyst expectations. The biotechnology firm reported better-than-anticipated financial results and raised its full-year guidance, sparking investor optimism.

For the quarter ended March 31, Adaptive Biotechnologies posted a loss of 20 cents per share, significantly better than the analysts' consensus estimate of a 29-cent loss. The company's revenue jumped 25.2% year-over-year to $52.44 million, surpassing Wall Street's expectations of $42.68 million. Notably, the Minimal Residual Disease (MRD) segment showed strong performance with revenue increasing 34% to $43.7 million, driven by robust growth in clinical volumes and improved average selling prices.

In light of the strong quarterly performance, Adaptive Biotechnologies raised its full-year MRD revenue guidance to $180-$190 million and lowered its expected operating expenses and cash burn. The positive results and outlook prompted JP Morgan to raise its price target for ADPT from $9 to $10. With a solid cash position of $233 million and improving financial metrics, Adaptive Biotechnologies appears well-positioned to continue its growth trajectory in the biotechnology sector.